Literature DB >> 22718262

Immunity to the respiratory pathogen Bordetella pertussis.

R Higgs1, S C Higgins, P J Ross, K H G Mills.   

Abstract

Bordetella pertussis causes whooping cough, a severe respiratory tract infection in infants and children, and also infects adults. Studies in murine models have shown that innate immune mechanisms involving dendritic cells, macrophages, neutrophils, natural killer cells, and antimicrobial peptides help to control the infection, while complete bacterial clearance requires cellular immunity mediated by T-helper type 1 (Th1) and Th17 cells. Whole cell pertussis vaccines (wP) are effective, but reactogenic, and have been replaced in most developed countries by acellular pertussis vaccines (aP). However, the incidence of pertussis is still high in many vaccinated populations; this may reflect sub-optimal, waning, or escape from immunity induced by current aP. Protective immunity generated by wP appears to be mediated largely by Th1 cells, whereas less efficacious alum-adjuvanted aP induce strong antibody Th2 and Th17 responses. New generation aP that induce Th1 rather than Th2 responses are required to improve vaccine efficacy and prevent further spread of B. pertussis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718262     DOI: 10.1038/mi.2012.54

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  106 in total

Review 1.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

Review 2.  Strategies and new developments to control pertussis, an actual health problem.

Authors:  María Emilia Gaillard; Daniela Bottero; Griselda Moreno; Martin Rumbo; Daniela Hozbor
Journal:  Pathog Dis       Date:  2015-08-09       Impact factor: 3.166

Review 3.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

Review 4.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

5.  The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.

Authors:  Andrew Preston
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

6.  Brief Report: Seroprevalence of Pertussis Infection in HIV-Infected Adults in the United States.

Authors:  Stephanie B Troy; Alexandria E-B Rossheim; DaShaunda D Hilliard; Tina D Cunningham
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

7.  Relationship of immunogenicity to protective potency in acellular pertussis vaccines.

Authors:  Dorothy Xing; Catpagavalli Asokanathan; Ying Hua Xu; Barbara Bolgiano; Alex Douglas-Bardsley; Shumin Zhang; Junzhi Wang; Michael Corbel
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Seroepidemiology of pertussis in Hangzhou, China, during 2009-2017.

Authors:  Yuyang Xu; Erping Xu; Shijun Liu; Wei Zheng; Xuechao Zhang; Jian Du; Xiaoping Zhang; Jun Wang; Xinren Che; Wenwen Gu; Yan Liu
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

Review 9.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

Review 10.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.